Asahi Kasei Pharma announces that Doptelet® Tablet 20 mg (generic name: avatrombopag maleate), for which it obtained exclusive distribution rights in Japan from Swedish Orphan Biovitrum Japan Co., Ltd. (Sobi Japan), has been listed on Japan's National Health Insurance (NHI) drug price standard today. The launch of the product is scheduled for June 1, 2023.
Avatrombopag is a thrombopoietin receptor agonist, which stimulates the production of platelets. It has been approved in the U.S., Europe, and China as an agent for improving thrombocytopenia in patients with chronic liver disease who are scheduled to undergo an invasive procedure¹. It is sold as Doptelet® in the U.S. and Europe by Swedish Orphan Biovitrum AB (Sobi), the parent company of Sobi Japan, and in China by Shanghai Fosun Pharmaceutical (Group) Co., Ltd.
By providing a new therapeutic option for improving thrombocytopenia in patients with chronic liver disease, Asahi Kasei Pharma aims to realize a society where “no one should have to give up doing what they love due to illness” in accordance with its mission “to sincerely care for each individual life and solve their unmet medical needs with a wealth of ideas and solid science.”
Product overview of Doptelet® Tablet 20 mg
Product name
Doptelet® Tablet 20 mg
Generic name
Avatrombopag maleate
Indication
Improving thrombocytopenia in patients with chronic liver disease who are scheduled to undergo an invasive procedure
Dosage and administration
For adults, ordinarily administer the following dosage of avatrombopag orally once per day after a meal for 5 days.
If platelet count prior to administration is at least 40,000/µL but less than 50,000/µL: 40 mg
If platelet count prior to administration is less than 40,000/µL: 60 mg
Manufacture
Swedish Orphan Biovitrum Japan Co., Ltd.
Sale
Asahi Kasei Pharma Corporation
Approval
March 27, 2023
NHI price listing
May 24, 2023
Launch of sale
June 1, 2023
NHI price
¥7106.60 for Doptelet® Tablet 20 mg
About Swedish Orphan Biovitrum AB
Founded in 2009, Sobi is a specialized international biopharmaceutical company headquartered in Stockholm, Sweden, transforming the lives of people with rare and debilitating diseases. Providing reliable access to innovative medicines in the areas of haematology, immunology and specialty care, Sobi has approximately 1,600 employees across Europe, North America, the Middle East, Asia and Australia. To learn more, visit https://www.sobi.com/